Minimal residual disease in childhood acute lymphoblastic leukemia: Current status and challenges

Shai Izraeli, Dalia Waldman

Research output: Contribution to journalReview articlepeer-review

Abstract

The pace of disappearance of leukemic blasts in response to therapy has long been recognized as the most important prognostic factor in childhood acute lymphoblastic leukemia (ALL). Recent technological advancements enable detection of submicroscopic leukemic cells. The extent of reduction in the level of minimal residual disease (MRD) during the first phase of therapy can be exploited for improved risk classification of children with ALL. Current prospective studies test the hypothesis that tailoring treatment to the level of MRD will improve patients' outcome.

Original languageEnglish
Pages (from-to)34-39
Number of pages6
JournalActa Haematologica
Volume112
Issue number1-2
DOIs
StatePublished - 2004
Externally publishedYes

Keywords

  • Acute lymphoblastic leukemia
  • Childhood
  • FACS
  • Minimal residual disease
  • PCR

Fingerprint

Dive into the research topics of 'Minimal residual disease in childhood acute lymphoblastic leukemia: Current status and challenges'. Together they form a unique fingerprint.

Cite this